The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.
Melissa Alsina
Research Funding - Celgene; Millennium
Robert L. Schlossman
No relevant relationships to disclose
Donna M. Weber
Consultant or Advisory Role - Novartis (U)
Research Funding - Novartis
Steven E. Coutre
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Sagar Lonial
Consultant or Advisory Role - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx
Research Funding - Bristol-Myers Squibb; Celgene; Merck; Millennium; Novartis; Onyx
Cristina Gasparetto
Honoraria - Celgene; Millennium
Ghulam Warsi
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Michael S. Ondovik
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Sutapa Mukhopadhyay
Employment or Leadership Position - Novartis
Carole S. Paley
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Honoraria - Novartis
Paul Gerard Guy Richardson
Consultant or Advisory Role - Celgene; Johnson & Johnson; Millennium; Novartis